* Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC)

* No dose-limiting toxicities and no treatment-related serious adverse events observed

* Xerostomia predominantly Grade 1

* 80% PSA50 response at doses ≥ 160 MBq

* 100% objective response rate (ORR) in patients with RECIST-measurable lesions, including two complete responses (CRs)

* The data represent the first clinical trial results for a Lead-212 (212Pb)-based PSMA-targeted radioligand therapy and highlight the potential of 212Pb-ADVC001 to enhance therapeutic options for patients with prostate cancer

* Phase 2 expansion will evaluate 160 MBq and 200 MBq of 212Pb-ADVC001 using a randomized multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes in three indications: mCRPC (chemo-naïve, and post-177Lu-PSMA) and hormone-sensitive prostate cancer (mHSPC)

Sydney, Australia - October 18, 2025 - AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today presented results from the Phase 1b dose escalation of the TheraPb Phase 1/2 clinical trial ( NCT05720130 ) at the European Society for Medical Oncology (ESMO) 2025 congress. The presentation featured the first clinical results of 212Pb-ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy in mCRPC.